Esmirtazapine + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Postmenopausal Symptoms
Conditions
Postmenopausal Symptoms, Menopause, Vasomotor Symptoms
Trial Timeline
Sep 15, 2004 → Jan 15, 2006
NCT ID
NCT00535288About Esmirtazapine + Placebo
Esmirtazapine + Placebo is a phase 3 stage product being developed by Merck for Postmenopausal Symptoms. The current trial status is completed. This product is registered under clinical trial identifier NCT00535288. Target conditions include Postmenopausal Symptoms, Menopause, Vasomotor Symptoms.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00631657 | Phase 3 | Completed |
| NCT00561821 | Phase 3 | Completed |
| NCT00506389 | Phase 3 | Completed |
| NCT00482612 | Phase 3 | Completed |
| NCT00560833 | Phase 3 | Completed |
| NCT00535288 | Phase 3 | Completed |
Competing Products
20 competing products in Postmenopausal Symptoms